Barclays Maintains NIO Underweight; 1-Year Target Signals ~26.6% Upside
November 29, 2025, 2:02 AM EST. Barclays has maintained coverage on NIO Inc. – Depositary Receipt with an Underweight rating. The research shows a 1-year price target of $6.96, indicating ~26.62% upside from the latest close of $5.50. The target range spans $3.03 to $9.45. The note cites $189,968MM in projected annual revenue and a non-GAAP EPS of -0.34. On the fund side, 479 institutions hold positions, with average portfolio weight at 0.15% and total shares up ~85.54% to 318,794K. The put/call ratio of 0.71 suggests a bullish tilt. Major holders include Aspex Management, UBS Group, Jane Street Group, WT Asset Management, and BNP Paribas Arbitrage. This summary reflects data from Fintel.
CIBC Upgrades Canadian National Railway (CNI) to Outperformer; ~18% Upside to $113.59
November 29, 2025, 1:44 AM EST. CIBC upgrades Canadian National Railway (CNI) from Neutral to Outperformer, signaling a constructive view with about 18% upside. The analyst's one-year target is $113.59, representing an 18.45% gain from the latest close of $95.90 and a forecast range of $97.25-$137.05. The note also projects annual revenue of $18,868M (+9.71%) and non-GAAP EPS of 9.62. On the ownership side, 1,104 funds hold CNI, with total shares near 448.7M and a -3.32% three-month drift. The put/call ratio of 1.15 suggests a bearish tilt. Key holders include Bill & Melinda Gates Foundation Trust, Royal Bank of Canada, TCI Fund Management, Bank of Montreal, and Caisse de Depot et Placement du Quebec.
Barclays Maintains Abercrombie & Fitch Equal-Weight; 1-Year Target ~$105.60, ~7.9% Upside
November 29, 2025, 1:43 AM EST. Barclays reaffirmed an Equal-Weight stance on Abercrombie & Fitch (ANF). As of Nov 17, 2025, the street expects a 1-year target of $105.60, implying ~7.89% upside from the latest close of $97.88. The target range runs from $78.78-$136.50. Projected annual revenue is $3,781MM (down -27.03%), with non-GAAP EPS of 5.71 (up 223.29%). Fund sentiment shows 859 funds with an average position of 0.16%; total ANF shares held by institutions total 55,082K, down -3.33% in the last 3 months. The put/call ratio is 1.69, signaling a bearish outlook. Notable holders include AQR Capital Management (reduced), and holdings by IJH, VTSMX, Wellington, and American Century increasing exposure.
Barclays Maintains Overweight on Dicks Sporting Goods (DKS) with ~43% Upside to $159.63
November 29, 2025, 1:40 AM EST. Barclays reiterates an Overweight stance on DKS (Dicks Sporting Goods) as of August 23, 2023. The analyst projects ~43.13% upside to a $159.63 target from a close of $111.53, with a target range of $136.35-$210.00. The forecast implies revenue of $12,512MM and non-GAAP EPS of $12.19. Fund sentiment shows broad ownership with 1,102 funds holding DKS and about 64.16MM shares, averaging 0.24% weight per position. The put/call ratio is 1.32, suggesting a bearish tilt. Notable holders include Lone Pine Capital (3.79%/3,266K) and Fidelity Contrafund (FCNTX) (2.78%/2,395K). ETFs like IJH, VTSMX, and NAESX have increased exposure to DKS.
HC Wainwright Reiterates Buy on Anavex Life Sciences (AVXL) with 778.85% Upside
November 29, 2025, 1:36 AM EST. HC Wainwright & Co. reiterated a Buy rating on Anavex Life Sciences (AVXL) on November 28, 2025, citing substantial upside in the coming year. The analyst's one-year price target averages $33.66, implying 778.85% upside from AVXL's $3.83 close. Targets span $24.24-$44.10. The firm estimates projected annual revenue of $313MM and a non-GAAP EPS of 0.13. Fund sentiment remains mixed, with 328 funds reporting positions and a put/call ratio of 1.51 signaling bearish tendencies. Notable holders include Vanguard and iShares Russell 2000 ETF, though ownership levels have shifted quarter to quarter. The report highlights broader market data on ownership, sentiment, and ETF exposure via Fintel.
HC Wainwright Reiterates HALO Buy; 1-Year PT $76.05, 6.5% Upside
November 29, 2025, 1:34 AM EST. HC Wainwright & Co. reiterates a Buy rating on Halozyme Therapeutics (HALO) after November 28, 2025 coverage. The 1-year price target is $76.05, about a 6.5% upside from the recent close of $71.40. The target range runs from $54.54 to $96.60. Halozyme's projected annual revenue is about $1.336B, with a non-GAAP EPS of 5.32. Fund sentiment remains constructive: 1,217 funds hold HALO, averaging 0.25% of portfolios, with total institutional shares at 146.7M (down 1.59% in three months). The put/call ratio is 0.41, suggesting bullish bias. Major holders include IJH, VTSMX, Arrowstreet, Invesco, and NAESX. Fintel highlights Halozyme's fundamentals, ownership data, sentiment, options flow, and more for investors.
Citigroup Maintains Buy on Flutter Entertainment (FLUT) with ~61% Upside Target
November 29, 2025, 1:18 AM EST. Citigroup reiterates a Buy rating on Flutter Entertainment (FLUT) as of November 28, 2025. The one-year price target averages $322.56, implying roughly 61.35% upside from the latest close of $199.92. Targets span $252.50 to $399.00. The projection calls for 11,950MM in revenue (−22.59%) and non-GAAP EPS of 7.03. On the funds side, there are 1,114 funds holding FLUT, with institutional shares around 186.6M and a put/call ratio of 0.31 signaling bullish sentiment. Major holders include Capital World Investors (7.03%), Caledonia (3.96%), Capital Research Global Investors (3.66%), AEPGX (3.28%), and Vanguard (3.25%). Fintel notes broad coverage of ownership, sentiment, and options data.
Telefónica (TEF) Valuation After a 17% One-Month Drop: Is the Stock Undervalued?
November 29, 2025, 1:16 AM EST. Telefónica (BME:TEF) has fallen about 17% in the last month, leaving investors weighing near-term headwinds against stronger longer-term returns. The stock still shows a positive 3- and 5-year TSR (about 25% and 36%), even as debt and competitive pressure loom. At current levels, the stock trades below analysts' targets: a consensus fair value of about €4.51 versus a last close near €3.74, signaling potential undervaluation in the base case. The bull case hinges on portfolio optimization and monetization of non-core assets (Argentina, Peru, Colombia, Uruguay, Ecuador), freeing capital and reducing geographic risk, while sharpening focus on core markets (Spain, Brazil, Germany, UK) to lift free cash flow and ROCE. Key risks remain high debt and intensifying competition, which could alter the outlook.
STMicroelectronics Valuation After Modest Rebound: Is STMPA Undervalued at $19.78?
November 29, 2025, 1:04 AM EST. STMicroelectronics (ENXTPA:STMPA) saw a modest week-long rebound of about 5% as investors weigh a tougher recent stretch against an improving sentiment. The stock remains ~17.4% in negative total shareholders return over the last year. With a fair value of $24.72 and current close around $19.78, the setup hints upside potential if forecasts for profitable growth materialize. Shares trade roughly 24% below consensus targets, suggesting the market has yet to fully price in an anticipated recovery in demand and margin expansion driven by EV/SiC leadership. Key risks include ongoing restructuring and inventory imbalances. On a relative basis, the P/E multiple sits at about 38x vs peers, implying potential re-rating toward the mid-40s if execution improves. Investors should weigh growth prospects against execution risk and sector headwinds.
SFL Corporation (NYSE:SFL) Valuation After Follow-On Offering and DRIP
November 29, 2025, 1:02 AM EST. SFL Corporation (NYSE:SFL) has announced a follow-on offering of 10 million new shares at $8.14, aiming to raise $81.4 million and featuring a dividend reinvestment plan (DRIP). The move injects capital while leveraging a diversified fleet with long-term charters to investment-grade counterparties, underpinning stable revenue. Momentum shows a ~13.7% lift in the past month, but the stock remains down ~21.1% year-to-date and ~12.3% over the last year, with five-year returns around 88.5%. On valuation, a last-close fair value of $9.43 signals undervaluation, while a DCF-based view near $8.11 argues for a more neutral stance. Investors should weigh new equity against headwinds in soft drilling markets and the redeployment of high-value assets.
Intel Maps Strategic Direction at TIMT Conference 2025: AI Push, Nvidia Partnership, and Margin Focus
November 29, 2025, 1:00 AM EST. At the RBC TIMT Conference 2025, Intel outlined its strategic path with John Pitzer leading the discussion. Key takeaways: focus on margin improvements and expanding market share amid supply constraints expected to peak in Q1 2026. A centerpiece is the planned $5 billion partnership with NVIDIA to deliver a custom Xeon for data centers, with NVIDIA integrating the chip and leading go-to-market. Intel is advancing its AI strategy across PC and server markets and developing inference-specialized GPUs to support agentic and physical AI. Management aims to bolster cost efficiency as data center margins remain under pressure. The note cautions that some AI stocks may offer greater upside with lower risk.
Bio-Techne TECH: ACA Subsidy News Spurs Momentum, but Valuation Remains Cautious
November 29, 2025, 12:04 AM EST. Bio-Techne (TECH) rose on reports the ACA subsidies may be extended, easing regulatory uncertainty in healthcare. The stock gained 4.84% last week and 18.09% over 90 days, even as the 1-year return sits at -13.91%. Our narrative notes the shares trade above fair value on optimism, with a fair value of $69.17 signaling an undervalued longer-term setup despite a lofty multiple. The stock's P/E of 129x far exceeds the industry average (~38x) and the fair ratio (~25.7x), signaling valuation risk. A shift from Exosome Diagnostics toward higher-margin core businesses supports expected operating-margin expansion (100-200 bps) and possible earnings growth, though biotech funding headwinds and tariffs remain risks. Read the full narrative for the roadmap.
